Basic & Clinical Medicine ›› 2024, Vol. 44 ›› Issue (7): 979-983.doi: 10.16352/j.issn.1001-6325.2024.07.0979

• Original Articles • Previous Articles     Next Articles

Antihypertensive drug-related gene polymorphisms in patients with primary hypertension in Guiyang region

ZOU Wenbing, WANG Anxian, CAO Zhengyuan*   

  1. Department of Medical Laboratory, Guihang Guiyang Hospital, Guiyang 550009, China
  • Received:2023-11-14 Revised:2024-01-23 Online:2024-07-05 Published:2024-06-26
  • Contact: *muron5365@163.com

Abstract: Objective To analyze the distribution bio-relationship of loci related antihypertensive drug efficacy in patients with essential hypertension (EH) in Guiyang region to support the development of clinical guidance for individualized medication of hypertension patients in this region. Methods A total of 406 EH patients who visited the Cardiology Department of Guiyang Hospital from December 2020 to December 2021 were collected as the study subjects and ligase sequencing method was applied to detect 7 gene loci of antihypertensive drugs. The distribution of gene loci in EH patients of different genders and from different geographic regions was evaluated. Results The mutation frequencies of the seven genes, CYP2D6*10(c.100 C>T),CYP2C9*3(c.1075 A>C),ADRB1(c.1165 G>C),AGTR1(c.1166 A>C),ACE(I/D),NPPA(T2238C) and CYP3A5*3(A6986G) were 47.29%, 5.91%, 73.15%, 6.65%, 34.24%, 0.49%, and 69.70% respectively; There was no significant difference in distribution frequency of hypertension drug related gene polymorphisms among different genders. Conclusions The distribution frequency of alleles in 7 antihypertensive drug efficacy related loci is not related to gender of patients.EH patients in Guiyang region are more sensitive to β-blockers and calcium antagonists, but less sensitive to other types of antihypertensive drugs. Therefore, the dose administered should be adjusted appropriately when using β-blockers and calcium antagonists.

Key words: Guiyang region, antihypertensive drug, genetic polymorphism, medication guidance

CLC Number: